Scarica l'app Stockscreener
3.64
2.82%
0.10
Precedente Chiudi:
$3.54
Aprire:
$3.62
Volume 24 ore:
3.56M
Relative Volume:
2.04
Capitalizzazione di mercato:
$378.13M
Reddito:
-
Utile/perdita netta:
$-166.01M
Rapporto P/E:
-1.7519
EPS:
-2.0778
Flusso di cassa netto:
$-131.32M
1 W Prestazione:
+1.11%
1M Prestazione:
+12.35%
6M Prestazione:
+6.12%
1 anno Prestazione:
+32.85%
Intervallo 1D:
$3.485
$3.76
Intervallo di 1 settimana:
$3.39
$3.845
Portata 52W:
$2.22
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Nome
Larimar Therapeutics Inc
Settore
Industria
Telefono
844-511-9056
Indirizzo
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.64 | 378.13M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-29 | Iniziato | Truist | Buy |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-10-03 | Iniziato | Wedbush | Outperform |
| 2024-10-02 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-03 | Iniziato | Leerink Partners | Outperform |
| 2023-11-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-19 | Iniziato | Guggenheim | Buy |
| 2022-02-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-02-01 | Iniziato | William Blair | Outperform |
Mostra tutto
Larimar Therapeutics Inc Borsa (LRMR) Ultime notizie
Larimar Therapeutics Inc (LRMR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Larimar Therapeutics Inc (LRMR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
Larimar Therapeutics Inc (LRMR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Larimar Therapeutics Inc (LRMR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Larimar Therapeutics (LRMR) Slides 3.6%: Technical Support Test in FocusTriple Bottom - newsline.com
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Friedreich's Ataxia: The Search For A True Disease-Modifying TherapyCan Larimar Deliver? - RTTNews
Larimar Therapeutics (LRMR) Faces Headwinds as Stock Slides 2.21% to $3.10Momentum Surge Alerts - newsline.com
LRMR Q1 2026 Earnings: EPS Surprise of 43% as Loss Narrows, Stock SlidesPost-Announcement Reaction - newsline.com
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
LRMR Q1 2026 Earnings: EPS Surprise of 43.19% as Net Loss Narrower Than ExpectedProfit Growth Outlook - newsline.com
Larimar Therapeutics (LRMR) Slides 4.3% as Selling Pressure Tests Key SupportFRAMA Signal - newsline.com
Larimar Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Bolsters Operational ProgressRevenue Warning Signal - newsline.com
Larimar Therapeutics (LRMR): Shares Hold Steady Near Support as Consolidation ContinuesBollinger Band - newsline.com
LRMR Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises as Pipeline Progress ContinuesEarnings Forecast Report - thelegaladvocate.com
J.P. Morgan Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $9 - Moomoo
JP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight Recommendation - MSN
LRMR Initiates Coverage by JP Morgan -- Rating Set at Overweight - GuruFocus
JPMorgan Initiates Larimar Therapeutics at Overweight With $9 Price Target - marketscreener.com
JPMorgan initiates Larimar Therapeutics stock at Overweight By Investing.com - Investing.com UK
JPMorgan initiates Larimar Therapeutics stock at Overweight - Investing.com India
80,590,392 Common Stock of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Stock Options of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Restricted Stock Units of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Certain Pre-Funded Warrants of Larimar Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2026. - marketscreener.com
Larimar Therapeutics (LRMR) Edges Lower as Stock Tests Key Support ZoneComposite Profile - newsline.com
Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study - MSN
[Form 4] Larimar Therapeutics, Inc. Insider Trading Activity - Stock Titan
Larimar Therapeutics (LRMR) entity tied to director receives 55,150 stock options - Stock Titan
Larimar Therapeutics (LRMR) awards 55,150 stock options to director - Stock Titan
Larimar Therapeutics (LRMR) director receives 55,150 stock options grant - Stock Titan
Larimar Therapeutics (LRMR) director awarded 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics (LRMR) director gets 55,150 stock options at $3.33 strike - Stock Titan
Larimar Therapeutics stockholders approve board elections and share increase By Investing.com - Investing.com Nigeria
Larimar Therapeutics stockholders approve board elections and share increase - Investing.com
Larimar Shareholders Approve Governance and Capital Structure Changes - TipRanks
Larimar Therapeutics (NASDAQ: LRMR) holders back big authorized share increase - Stock Titan
LRMR Maintained by Wedbush -- Price Target Lowered to $12.00 - GuruFocus
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Larimar Therapeutics Price Target Cut to $12.00/Share From $13.00 by Wedbush - Moomoo
Larimar Therapeutics (LRMR) surges on FDA breakthrough therapy designation - MSN
Wedbush Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
Number of shareholders of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Wedbush Adjusts Larimar Therapeutics Price Target to $12 From $13, Maintains Outperform Rating - Moomoo
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress - The Globe and Mail
Exploring US High Growth Tech Stocks This May 2026 - Yahoo Finance
Citizens reiterates Larimar Therapeutics stock rating on FDA progress By Investing.com - Investing.com South Africa
Larimar Therapeutics Inc Azioni (LRMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):